Evaxion announces Executive Management Changes to strengthen the AI-strategy

COPENHAGEN, Denmark, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced: Evaxion has hired a new Chief Executive Officer (“CEO”) to accelerate the strategic development and execution of the vast business opportunities at hand after having matured the Company’s AI platforms over the past 15 years. “We are truly proud to announce that

Related Keywords

Russia ,Denmark ,Copenhagen ,Køavn ,New York ,United States ,Ukraine ,Christian Kanstrup ,As Marianne Soegaard ,Marianne Soegaard ,Exchange Commission ,Securities Exchange ,Novo Nordisk ,Chief Executive Officer ,Progression Free Survival ,Evaxion Biotech ,Per Norl ,Nasdaq New York ,Securities Act ,Securities Exchange Act ,Annual Report ,Founder For ,Investor Relations ,Business Opportunities ,Strategy Development ,Mmunotherapies ,Strategic Development ,Christian ,Biotechnology Company ,Chairman Of The Board ,Clinical Data ,Product Development ,